Nugenerex Immuno-oncology, Inc.
CIK 0001804585
Revenue (TTM)
$0
Q3 Jun 2021
Net Income (TTM)
−$6.09M
−37.5% YoY
Q3 Jun 2021
EPS Diluted (TTM)
—
Q3 Jun 2021
Gross Margin
—
Q3 Jun 2021
Operating Margin
—
Q3 Jun 2021
Net Margin
—
Q3 Jun 2021
Free Cash Flow (TTM)
—
Q3 Jun 2021
Cash
—
Q3 Jun 2021
Total Debt
—
Q3 Jun 2021
Shares Outstanding
100.3M sh
Q3 Jun 2021
Revenue & Net Income
Revenue Growth (YoY)
No data available for this metric.